Barclays Maintains Overweight on Abbott Laboratories, Raises Price Target to $141
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Matt Miksic has maintained an Overweight rating on Abbott Laboratories (NYSE:ABT) and increased the price target from $133 to $141, indicating a positive outlook on the company's stock.
January 26, 2024 | 6:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays analyst Matt Miksic maintains an Overweight rating on Abbott Laboratories and raises the price target from $133 to $141, suggesting confidence in the company's future performance.
The increase in price target by Barclays reflects a bullish stance on Abbott Laboratories, which could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100